Fate therapeutics inc (FATE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Collaboration revenue

2,515

2,802

2,429

2,817

2,632

1,661

1,026

1,027

1,026

1,027

1,026

1,026

1,027

1,027

1,026

1,027

1,322

-

1,026

329

-

-

-

-

-

0

209

208

209

208

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

82

263

320

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

209

290

472

528

Operating expenses:
Research and development

29,278

25,209

23,202

21,631

17,728

14,095

13,637

16,816

11,476

9,887

8,578

7,927

7,966

6,230

6,804

6,782

6,636

5,433

5,003

4,857

4,568

3,865

4,080

3,968

4,522

3,031

3,378

3,067

2,531

3,315

General and administrative

7,729

6,671

6,346

5,270

5,350

4,307

4,081

3,816

3,604

3,384

2,788

2,669

3,032

2,451

2,611

2,249

2,602

2,555

2,351

2,690

2,756

2,078

1,904

2,072

2,415

1,871

1,979

1,492

1,297

863

Total operating expenses

37,007

31,880

29,548

26,901

23,078

18,402

17,718

20,632

15,080

13,271

11,366

10,596

10,998

8,681

9,415

9,031

9,238

7,988

7,354

7,547

7,324

5,943

5,984

6,040

6,937

4,902

5,357

4,559

3,828

4,178

Loss from operations

-34,492

-29,078

-27,119

-24,084

-20,446

-16,741

-16,692

-19,605

-14,054

-12,244

-10,340

-9,570

-9,971

-7,654

-8,389

-8,004

-7,916

-6,912

-6,328

-7,218

-7,324

-5,943

-5,984

-6,040

-6,937

-4,902

-5,148

-4,269

-3,356

-3,650

Other income (expense):
Interest income

972

1,314

910

1,015

1,091

1,144

339

376

331

159

152

137

111

43

37

31

27

3

4

2

1

-

-

1

-

3

2

0

1

-

Interest expense

-

538

400

409

405

430

429

425

412

412

378

212

266

329

385

435

488

537

562

563

558

291

187

28

43

378

230

88

100

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-118

-

-

-

-

-

-

-

-

-

-

-

-432

-

-

-

-

-

-

-

Change in fair value of exchangeable shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,409

728

1,155

105

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

-31

22

-12

-

Total other income, net

972

776

510

606

686

714

-90

-49

-81

-253

-344

-75

-155

-286

-348

-404

-461

-534

-558

-561

-557

-290

-619

-27

-43

-837

-925

-1,265

-192

-463

Net loss

-33,520

-28,302

-26,609

-23,478

-19,760

-16,027

-16,782

-19,654

-14,135

-12,497

-10,684

-9,645

-10,126

-7,940

-8,737

-8,408

-8,377

-7,446

-6,886

-7,779

-7,881

-6,233

-6,603

-6,067

-6,980

-5,739

-6,073

-5,534

-3,548

-4,113

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities, net

120

-29

-42

93

2

12

1

-2

-10

10

26

-5

-33

-4

-8

-3

14

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-33,400

-28,331

-26,651

-23,385

-19,758

-16,015

-16,781

-19,656

-14,145

-12,487

-10,658

-9,650

-10,159

-7,944

-8,745

-8,411

-8,363

-7,446

-6,886

-7,779

-7,881

-

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-0.44

-0.38

-0.40

-0.36

-0.30

-0.24

-0.31

-0.37

-0.27

-0.29

-0.26

-0.23

-0.24

-0.20

-0.27

-0.29

-0.29

-0.23

-0.24

-0.33

-0.38

-0.31

-0.32

-0.30

-0.34

8.65

-4.81

-4.46

-2.92

-3.51

Weighted-average common shares used to compute basic and diluted net loss per share

75,886

75,699

66,929

65,213

64,920

64,703

54,185

53,130

52,763

43,705

41,428

41,406

41,388

37,280

32,090

28,868

28,777

28,811

28,650

23,920

20,554

20,503

20,489

20,467

20,346

19,869

1,262

1,239

1,213

1,171